In 1979, Klausner joined the
National Institutes of Health (NIH) as a postdoctoral fellow. At age 30, Klausner was appointed to the chief of the cell biology and metabolism branch of the
National Institute of Child Health and Human Development. He was the managing partner of the biotech venture capital firm, the
Column Group. He was a member of the
Searle Scholars advisory board. He was a scientific advisor at the
Fred Hutchinson Cancer Research Center. He has been an Advisor to the Presidents of the Academies for counter-terrorism and a liaison to the White House Office of Science & Technology Policy, and was the chief strategy advisor for
USAID. Klausner co-founded
Juno Therapeutics in 2013, GRAIL in 2015. In 2022, Klausner co-founded
Altos Labs and is currently Chief Scientist and Board Co-Chairman of the company. He was president of the
American Society for Clinical Investigation from 1995 to 1996.
Research His research focused on
T cells and the potential for
CAR-T therapies. He also has published research on the genetics of
Von Hippel–Lindau disease, a condition which predisposes a person to developing cancer. He is an author of more than 300 scientific articles. == Personal life ==